| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NVAX | Common Stock | Options Exercise | $389K | +15.2K | +74.07% | $25.60 | 35.7K | Jul 1, 2021 | Direct | F1 |
| transaction | NVAX | Common Stock | Options Exercise | $728K | +19.9K | +55.72% | $36.60 | 55.6K | Jul 1, 2021 | Direct | F1 |
| transaction | NVAX | Common Stock | Options Exercise | $2.12M | +17.6K | +31.61% | $121.00* | 73.1K | Jul 1, 2021 | Direct | F1 |
| transaction | NVAX | Common Stock | Sale | -$428K | -2.05K | -2.8% | $209.20 | 71.1K | Jul 1, 2021 | Direct | F1, F2 |
| transaction | NVAX | Common Stock | Sale | -$1.28M | -6.11K | -8.59% | $210.02 | 65K | Jul 1, 2021 | Direct | F1, F3 |
| transaction | NVAX | Common Stock | Sale | -$869K | -4.12K | -6.34% | $211.07 | 60.8K | Jul 1, 2021 | Direct | F1, F4 |
| transaction | NVAX | Common Stock | Sale | -$1.36M | -6.42K | -10.55% | $212.15 | 54.4K | Jul 1, 2021 | Direct | F1, F5 |
| transaction | NVAX | Common Stock | Sale | -$2.71M | -12.7K | -23.34% | $213.07 | 41.7K | Jul 1, 2021 | Direct | F1, F6 |
| transaction | NVAX | Common Stock | Sale | -$2.77M | -12.9K | -30.96% | $214.13 | 28.8K | Jul 1, 2021 | Direct | F1, F7 |
| transaction | NVAX | Common Stock | Sale | -$1.5M | -6.98K | -24.24% | $214.97 | 21.8K | Jul 1, 2021 | Direct | F1, F8 |
| transaction | NVAX | Common Stock | Sale | -$287K | -1.33K | -6.09% | $215.70 | 20.5K | Jul 1, 2021 | Direct | F1, F9 |
| transaction | NVAX | Common Stock | Options Exercise | $919K | +25.1K | +122.57% | $36.60 | 45.6K | Jul 2, 2021 | Direct | F1 |
| transaction | NVAX | Common Stock | Options Exercise | $3.32M | +27.4K | +60.15% | $121.00* | 73.1K | Jul 2, 2021 | Direct | F1 |
| transaction | NVAX | Common Stock | Sale | -$414K | -1.97K | -2.7% | $210.23 | 71.1K | Jul 2, 2021 | Direct | F1, F10 |
| transaction | NVAX | Common Stock | Sale | -$896K | -4.24K | -5.97% | $211.21 | 66.8K | Jul 2, 2021 | Direct | F1, F11 |
| transaction | NVAX | Common Stock | Sale | -$1.62M | -7.62K | -11.39% | $212.29 | 59.2K | Jul 2, 2021 | Direct | F1, F12 |
| transaction | NVAX | Common Stock | Sale | -$503K | -2.36K | -3.98% | $213.38 | 56.9K | Jul 2, 2021 | Direct | F1, F13 |
| transaction | NVAX | Common Stock | Sale | -$959K | -4.47K | -7.85% | $214.76 | 52.4K | Jul 2, 2021 | Direct | F1, F14 |
| transaction | NVAX | Common Stock | Sale | -$1.12M | -5.19K | -9.9% | $215.74 | 47.2K | Jul 2, 2021 | Direct | F1, F15 |
| transaction | NVAX | Common Stock | Sale | -$649K | -2.99K | -6.34% | $216.92 | 44.2K | Jul 2, 2021 | Direct | F1, F16 |
| transaction | NVAX | Common Stock | Sale | -$2.17M | -9.97K | -22.54% | $217.84 | 34.3K | Jul 2, 2021 | Direct | F1, F17 |
| transaction | NVAX | Common Stock | Sale | -$1.62M | -7.42K | -21.67% | $218.77 | 26.8K | Jul 2, 2021 | Direct | F1, F18 |
| transaction | NVAX | Common Stock | Sale | -$1.11M | -5.03K | -18.75% | $219.76 | 21.8K | Jul 2, 2021 | Direct | F1, F19 |
| transaction | NVAX | Common Stock | Sale | -$139K | -628 | -2.88% | $220.80 | 21.2K | Jul 2, 2021 | Direct | F1, F20 |
| transaction | NVAX | Common Stock | Sale | -$150K | -675 | -3.19% | $221.53 | 20.5K | Jul 2, 2021 | Direct | F1, F21 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NVAX | Stock Option (Right to Buy) | Options Exercise | $0 | -15.2K | -100% | $0.00* | 0 | Jul 1, 2021 | Common Stock | 15.2K | $25.60 | Direct | F1, F22 |
| transaction | NVAX | Stock Option (Right to Buy) | Options Exercise | $0 | -19.9K | -44.18% | $0.00 | 25.1K | Jul 1, 2021 | Common Stock | 19.9K | $36.60 | Direct | F1, F23 |
| transaction | NVAX | Stock Option (Right to Buy) | Options Exercise | $0 | -17.6K | -39.02% | $0.00 | 27.4K | Jul 1, 2021 | Common Stock | 17.6K | $121.00 | Direct | F1, F24 |
| transaction | NVAX | Stock Option (Right to Buy) | Options Exercise | $0 | -25.1K | -100% | $0.00* | 0 | Jul 2, 2021 | Common Stock | 25.1K | $36.60 | Direct | F1, F23 |
| transaction | NVAX | Stock Option (Right to Buy) | Options Exercise | $0 | -27.4K | -100% | $0.00* | 0 | Jul 2, 2021 | Common Stock | 27.4K | $121.00 | Direct | F1, F24 |
| Id | Content |
|---|---|
| F1 | The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
| F2 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $208.56 to $209.54, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F3 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.57 to $210.54, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F4 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.57 to $211.47, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F5 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.58 to $212.57, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F6 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.60 to $213.58, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F7 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.61 to $214.60, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F8 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.63 to $215.55, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F9 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.63 to $215.84, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F10 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.75 to $210.74, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F11 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.82 to $211.75, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F12 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.82 to $212.79, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F13 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.87 to $213.84, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F14 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.20 to $215.16, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F15 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.24 to $216.17, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F16 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.26 to $217.18, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F17 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.28 to $218.27, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F18 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.33 to $219.30, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F19 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.33 to $220.27, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F20 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.34 to $221.20, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F21 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.38 to $222.33, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| F22 | The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 1, 2012 grant date. |
| F23 | The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 2, 2013 grant date. |
| F24 | The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 6, 2014 grant date. |